Figure S2: Screening with drugs compared with DMSO control. from Identification of a RAS-activating TMEM87A–RASGRF1 Fusion in an Exceptional Responder to Sunitinib with Non–Small Cell Lung Cancer

MLA

Geoffrey R. Oxnard, et al. Figure S2: Screening with Drugs Compared with DMSO Control. from Identification of a RAS-Activating TMEM87A–RASGRF1 Fusion in an Exceptional Responder to Sunitinib with Non–Small Cell Lung Cancer. Mar. 2023. EBSCOhost, https://doi.org/10.1158/1078-0432.22477763.v1.

APA

Geoffrey R. Oxnard, Pasi A Jänne, Lynette M. Sholl, Nikhil Wagle, Michael S. Rabin, Daniel B. Costa, Tom Nguyen, Deepa Rangachari, Jiaqi Li, Emily S. Chambers, Suzanne E. Dahlberg, Sasha Kravets, Sarah E. Clifford, Dewey Kim, Yoshihisa Kobayashi, & Alissa J. Cooper. (2023). Figure S2: Screening with drugs compared with DMSO control. from Identification of a RAS-activating TMEM87A–RASGRF1 Fusion in an Exceptional Responder to Sunitinib with Non–Small Cell Lung Cancer. https://doi.org/10.1158/1078-0432.22477763.v1

Chicago

Geoffrey R. Oxnard, Pasi A Jänne, Lynette M. Sholl, Nikhil Wagle, Michael S. Rabin, Daniel B. Costa, Tom Nguyen, et al. 2023. “Figure S2: Screening with Drugs Compared with DMSO Control. from Identification of a RAS-Activating TMEM87A–RASGRF1 Fusion in an Exceptional Responder to Sunitinib with Non–Small Cell Lung Cancer,” March. doi:10.1158/1078-0432.22477763.v1.